Compare LYEL & LWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYEL | LWAY |
|---|---|---|
| Founded | 2018 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.8M | 368.4M |
| IPO Year | 2021 | 1995 |
| Metric | LYEL | LWAY |
|---|---|---|
| Price | $12.57 | $23.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $30.60 | ★ $34.50 |
| AVG Volume (30 Days) | 61.8K | ★ 151.3K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.33 |
| EPS | N/A | ★ 0.30 |
| Revenue | $36,000.00 | ★ $103,350,000.00 |
| Revenue This Year | N/A | $16.64 |
| Revenue Next Year | $8,712.13 | $17.28 |
| P/E Ratio | ★ N/A | $75.30 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.49 | $17.31 |
| 52 Week High | $45.00 | $34.20 |
| Indicator | LYEL | LWAY |
|---|---|---|
| Relative Strength Index (RSI) | 22.77 | 38.83 |
| Support Level | $12.15 | $21.11 |
| Resistance Level | $13.62 | $27.88 |
| Average True Range (ATR) | 1.36 | 1.25 |
| MACD | -0.27 | -0.34 |
| Stochastic Oscillator | 3.08 | 13.94 |
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir, which is a cultured dairy product. Its product categories are Drinkable Kefir, which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir, and Other dairy. The company manufactures and markets products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through a direct sales force, brokers, and distributors.